Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Diseases Crohn

George-Hyslop, and K. A. Siminovitch. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 36 471 —475 (2004). [Pg.575]

Remicade Crohn disease, arthritis Johnson Johnson, Schering-Plough... [Pg.7]

TNF-a is a cytokine produced by T cells and mast cells. TNF-a is involved in the gut inflammatory process in Crohn disease, where treatment with soluble TNF-a receptor and anti-TNF-a antibodies and soluble TNF-a receptor has the highest... [Pg.182]

Cya n ocobalamin (Bir) Homocysteine methyltransferase Methylmalonyi CoA mutase Methionine, SAM Odd-carbon fatty acids, Val, Met, He, Thr MCC pernicious anemia. Also in aging, especially with poor nutrition, bacterial overgrowth of terminal ileum, resection of the terminal ileum secondary to Crohn disease, chronic pancreatitis, and, rarely, vegans, or infection with D. latum Megaloblastic (macrocytic) anemia Progressive peripheral neuropathy. ... [Pg.144]

Louis, E., Vermeire, S., Rutgeerts, P., et al. (2002) A positive response to infliximab in Crohn disease association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand. J. Gastroenterol. 37, 818-824. [Pg.410]

Panaccione R, Sandborn WJ. Medical therapy of Crohn disease. Curr Opin Gastroenterol 2004 20 351-9. [Pg.86]

Adults - Take 9 mg once daily in the morning for up to 8 weeks. Swallow capsules whole do not chew or break. For recurring episodes of active Crohn disease, a repeat 8-week course of budesonide can be given. Following an 8-week course of treatment for active disease and once the patient s symptoms are controlled (Crohn Disease Activity Index less than 150), budesonide 6 mg is recommended once daily for maintenance of clinical remission for up to 3 months. If symptom control is still maintained at 3 months, an attempt to taper to complete cessation is recommended. Continued treatment with budesonide 6 mg for more than 3 months has not been shown to provide substantial clinical benefit. [Pg.256]

Patients with mild to moderately active Crohn disease involving the ileum or ascending colon have been switched from oral prednisolone to budesonide with no reported episodes of adrenal insufficiency. Because prednisolone should not be stopped abruptly, tapering should begin concomitantly with initiating budesonide treatment. [Pg.256]

Crohn disease, moderate to severe For reducing signs and symptoms and inducing and maintaining clinical remission in patients with moderately to severely active Crohn disease who have had an inadequate response to conventional therapy. [Pg.2016]

Crohn disease, fistulizing For reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure. [Pg.2016]

Elevated concentrations of TNF have been found in the joints of RA patients and the stools of Crohn disease patients and correlate with elevated disease activity. In Crohn disease, infliximab reduces infiltration of inflammatory cells and TNF production in inflamed areas of the intestine and reduces the proportion of mononuclear cells from the lamina propria able to express TNF and interferon. In RA, treatment with infliximab reduced infiltration of inflammatory cells into inflamed areas of the joint as well as expression of molecules mediating cellular adhesion and vascular cell adhesion molecule-1, chemoattraction, and tissue degradation. After treatment with infliximab, patients with Crohn disease or RA have decreased levels of serum IL-6 and C-reactive protein compared with baseline. [Pg.2017]

Pharmacokinetics A study of single IV infusions of 3 to 20 mg/kg in Crohn disease or RA patients showed a linear relationship between the dose and the maximum serum concentration. The volume of distribution at steady state was independent of dose and indicated that infliximab was distributed primarily within the vascular compartment. The median terminal half-life of infliximab ranged between 8 to 9.5 days. [Pg.2017]

Children Safety and efficacy in patients with juvenile rheumatoid arthritis and in pediatric patients with Crohn disease have not been established. [Pg.2019]

The most common reasons for discontinuation of treatment were infusion-related reactions (ie, dyspnea, flushing, headache, rash). Adverse events have been reported in a higher proportion of RA patients receiving the 10 mg/kg dose than the 3 mg/kg dose however, no differences were observed in the frequency of adverse events between the 5 and 10 mg/kg doses in patients with Crohn disease. [Pg.2020]

Many attempts have been made to link monoclonal antibodies specific for antigenic determinants on cancer cells to protein toxins such as ricin (Box 29-A). It is hoped that this may provide an effective way of carrying toxins into cancer cells/ 1 r Therapeutic human monoclonal antibodies are already in use as antirejection drugs for kidney transplantation, for treatment of rheumatoid arthritis, Crohn disease, and for some types of cancer/... [Pg.1841]

Gastrointestinal disorders Decreased inflammation Crohn disease, ulcerative colitis... [Pg.424]

Sparano JA, Brandt LJ, Dutcher JP, DuBois JS, Atkins MB. Symptomatic exacerbation of Crohn disease after treatment with high-dose interleukin-2. Ann Intern Med 1993 118(8) 617-18. [Pg.68]

Ghntborg B. Pancreatitis hos en patient med morbus Crohn behandlet med mesalazin og azathioprin. [Pancreatitis in a patient with Crohn disease treated with mesalazine and azathioprine.] Ugeskr Laeger 2000 162(34) 4553. ... [Pg.147]

Pearson DC, May GR, Pick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995 123(2) 132M2. [Pg.384]

Porges Y, Blumen S, Fireman Z, Sternberg A, Zamir D. Cyclosporme-mduced optic neuropathy, ophthalmoplegia, and nystagmus in a patient with Crohn disease. Am J Ophthalmol 1998 126(4) 607-9. [Pg.763]

Plein K, Burkard G, Hotz J. Behandlung der chronischen Diarrhoe beim Morbus Crohn. Eine Pilotstudie zur kUnischen Wirkung von Tanninalbuminat und Ethacridinlactat. [Treatment of chronic diarrhea in Crohn disease. A pilot study of the clinical effect of tannin albuminate and ethacridine lactate.] Fortschr Med 1993 111(7) 114-18. [Pg.1282]

Reichardt P, Dahnert I, Tiller G, Hausler HJ. Possible activation of an intramyocardial inflammatory process Staphylococcus aureus) after treatment with infliximab in a boy with Crohn disease. Eur J Pediatr 2002 161(5) 281-3. [Pg.1753]

Mantyh, C.R, Gates, T.S., Zimmerman, R.P. et al. (1988). Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in h concentrations by arterioles, venules, and lymph nodules in sutgjcal specimens obtained from patients with ulcerative colitis and Crohn disease. Proc. Natl. Acad. Sci. USA 85, 3235-3239. [Pg.142]

Most recent evidence indicates that DFAs can even protect the intestinal tract against agressive agents favor the assimilation of antioxidants, and act as a druglike food for the treatment of colon ailments such as inflammatory bowel disease (Crohn disease). The development of efficient methodologies for the preparation of DFA-enriched caramels, compatible with the food and agricultural industry regulations, may lead to new natural functional foods and nutraceuticals based on DFAs in the near future. [Pg.50]

Answer A. Etanercept binds to tumor necrosis factor (TNF), resulting in the inactivation of this cytokine, which plays a major role in a number of inflammatory disorders including Crohn disease and rheumatoid arthritis. In the synovium, TNF recruits inflammatory cells and leads to neoangiogenesis and joint destruction. Infliximab, a monoclonal antibody, also inactivates TNF. [Pg.261]


See other pages where Diseases Crohn is mentioned: [Pg.582]    [Pg.183]    [Pg.254]    [Pg.2016]    [Pg.2018]    [Pg.2019]    [Pg.69]    [Pg.1855]    [Pg.1865]    [Pg.273]    [Pg.388]    [Pg.608]    [Pg.610]    [Pg.274]    [Pg.291]    [Pg.2328]    [Pg.99]    [Pg.339]    [Pg.657]    [Pg.36]    [Pg.73]   
See also in sourсe #XX -- [ Pg.1855 ]

See also in sourсe #XX -- [ Pg.274 ]

See also in sourсe #XX -- [ Pg.50 , Pg.73 ]

See also in sourсe #XX -- [ Pg.56 , Pg.61 , Pg.62 , Pg.124 , Pg.125 , Pg.185 , Pg.189 , Pg.216 ]

See also in sourсe #XX -- [ Pg.282 , Pg.358 , Pg.365 , Pg.372 , Pg.373 ]

See also in sourсe #XX -- [ Pg.50 , Pg.95 , Pg.171 ]




SEARCH



Colon Crohn s disease

Crohn

Crohn disease activity

Crohn’s Disease Activity

Crohn’s disease

Crohn’s disease clinical presentation

Crohn’s disease pathophysiology

Crohn’s disease treatment

Fistula in Crohn’s disease

Small Crohn disease

Thiopurines Crohn disease

© 2024 chempedia.info